Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Prostate cancer. Chemotherapy.

|August 1, 1987

Summary

This summary is machine-generated.

Chemotherapy offers limited benefits for metastatic hormone refractory prostate cancer. While some patients respond, overall survival advantages remain unproven, necessitating data collection on risks and benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mechanical reliability, surgical complications, and patient and partner satisfaction of the modern three-piece inflatable penile prosthesis.

Urology·1998

Same author

Extracorporeal shock-wave lithotripsy for bile duct calculi.

American journal of surgery·1998

Same author

Extracorporeal shock wave lithotripsy for obstructing pancreatic duct calculi.

The Journal of urology·1997

Same author

Pubovaginal slings using fascia lata for the treatment of intrinsic sphincter deficiency.

The Journal of urology·1997

Same author

Prostate carcinoma. Surgical management of regional disease.

Cancer·1996

Same author

Prostate specific antigen detected prostate cancer.

The Journal of urology·1996

Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026

Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026

Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026

Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026

Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026

Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026

See all related articles

Area of Science:

Oncology
Medical Oncology
Prostate Cancer Research

Background:

Metastatic hormone-refractory prostate cancer (mHRPC) presents significant treatment challenges.
Chemotherapeutic agents show variable efficacy in mHRPC patients.
Current treatments lack substantial overall survival benefits.

Purpose of the Study:

To evaluate the efficacy and safety of chemotherapy in mHRPC.
To assess the impact of chemotherapy on patient survival and response duration.
To emphasize the need for data collection in clinical protocols for mHRPC treatment.

Main Methods:

Review of existing clinical data on chemotherapy for mHRPC.
Analysis of objective response rates and survival data.

Related Experiment Videos

Comparison of single-agent versus combination chemotherapy efficacy.

Main Results:

Individual patient responses to chemotherapy vary, but overall objective response rates are low.
Response duration is often short, with no demonstrated overall survival advantage.
Combination chemotherapy has not proven superior to single-agent chemotherapy in phase III trials.

Conclusions:

Chemotherapy offers modest benefits for mHRPC, with significant limitations in response and survival.
Further research and data collection are crucial to understand the risks and benefits of chemotherapy in mHRPC.
Standardized protocols are needed to gather reliable data on chemotherapy's role in mHRPC management.